A new study from Wecare Probiotics indicates that Akkermansia muciniphila Akk11 may offer significant neuroprotective benefits in a mouse model of Parkinson's Disease (PD). Published in Probiotics and Antimicrobial Proteins, the research demonstrates Akk11's potential to mitigate neuronal damage and motor impairment. The study, conducted on 8-week-old male C57BL/6J mice, explored the effects of Akk11 in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD model. Researchers divided the mice into four groups: untreated control, MPTP-induced, MPTP-induced with Akk11 treatment, and Akk11-only.
Key Findings:
Significant Reduction in Motor Impairment: Mice treated with Akk11 showed a 29% improvement in motor function, measured through the pole test, rotarod test, and open field test, compared to the MPTP-only group.
Increased Dopaminergic Neuron Survival: Akk11 treatment resulted in a 35% increase in tyrosine hydroxylase (TH)-positive neurons in the substantia nigra, indicating a protective effect against dopaminergic neuron loss.
Inflammatory Response Mitigation: Akk11 reduced the expression of pro-inflammatory cytokines, such as IL-1β, TNF-α, and IL-6, by 40% while increasing anti-inflammatory cytokines, like TGF-β, IL-10, and Arg-1, by 30% in the brain regions of the treated mice.
NLRP3 Inflammasome Inhibition: Akk11 significantly suppressed the activation of the NLRP3 inflammasome, a key driver of neuroinflammation, showing a 50% reduction in NLRP3, ASC, caspase-1, and IL-1β expression.
Gut Health Improvement: Akk11 treatment led to a 25% increase in tight junction proteins, such as ZO-1 and Occludin, in the colon, suggesting improved gut barrier function.
Restoration of Microbiota diversity: Akk11 treatment restored the diversity of the gut microbiota, which was significantly reduced due to the MPTP treatment.
"Our research strongly suggests that Akk11 has the potential to attenuate the symptoms and severity of Parkinson's-related neuronal damage," stated Zhe Wang, lead author of the study with Wecare Probiotics. "By modulating neuroinflammation and enhancing gut barrier function, Akk11 offers a promising avenue for future therapeutic interventions."
Methodological Rigor:
The study employed a comprehensive approach, integrating 16S rRNA sequencing for gut microbiota analysis, RT-qPCR for gene expression quantification, and immunohistochemistry for protein localization and quantification. These methodologies provided robust data to support the observed neuroprotective effects of Akk11.
Future Directions:
While these preclinical findings are promising, further investigations, including human clinical trials, are warranted to validate the therapeutic efficacy of Akk11 in PD. This study contributes to the growing body of evidence supporting the gut-brain axis as a potential therapeutic target for neurodegenerative disorders.
Source: https://doi.org/10.1007/s12602-025-10499-1
https://www.wecare-life.com/WecLac/akkermansia-muciniphia-akk11.html
Wecare Probiotics
About Author
